US FDA staff questions Glaxo kidney cancer drug - Reuters
HispanicBusiness.comUS FDA staff questions Glaxo kidney cancer drugReutersWASHINGTON, Oct 1 (Reuters) - The US Food and Drug Administration's review staff expressed doubts that GlaxoSmithKline Plc's (GSK.L) (GSK. ...Liver Risk Seen in Glaxo's Proposed Kidney-Cancer DrugWall Street JournalFDA Plan Seeks Better Communication with PublicAboutLawsuits.comall 302 news articles��
Blog Content
No comments:
Post a Comment